Abstract: The present invention relates to an amorphous compound represented by chemical formula 1, a preparation method therefor, and a pharmaceutical composition comprising same. The amorphous compound represented by chemical formula 1 according to the present invention may be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317030836-STATEMENT OF UNDERTAKING (FORM 3) [29-04-2023(online)].pdf | 2023-04-29 |
| 2 | 202317030836-REQUEST FOR EXAMINATION (FORM-18) [29-04-2023(online)].pdf | 2023-04-29 |
| 3 | 202317030836-FORM 18 [29-04-2023(online)].pdf | 2023-04-29 |
| 4 | 202317030836-FORM 1 [29-04-2023(online)].pdf | 2023-04-29 |
| 5 | 202317030836-DRAWINGS [29-04-2023(online)].pdf | 2023-04-29 |
| 6 | 202317030836-DECLARATION OF INVENTORSHIP (FORM 5) [29-04-2023(online)].pdf | 2023-04-29 |
| 7 | 202317030836-COMPLETE SPECIFICATION [29-04-2023(online)].pdf | 2023-04-29 |
| 8 | 202317030836.pdf | 2023-05-03 |
| 9 | 202317030836-Verified English translation [04-05-2023(online)].pdf | 2023-05-04 |
| 10 | 202317030836-Proof of Right [26-05-2023(online)].pdf | 2023-05-26 |
| 11 | 202317030836-FORM-26 [21-07-2023(online)].pdf | 2023-07-21 |
| 12 | 202317030836-FORM 3 [26-09-2023(online)].pdf | 2023-09-26 |
| 13 | 202317030836-Certified Copy of Priority Document [10-10-2023(online)].pdf | 2023-10-10 |
| 14 | 202317030836-FER.pdf | 2025-05-14 |
| 15 | 202317030836-FORM 3 [08-08-2025(online)].pdf | 2025-08-08 |
| 16 | 202317030836-FORM 4 [12-11-2025(online)].pdf | 2025-11-12 |
| 1 | 202317030836_SearchStrategyNew_E_202317030836E_13-05-2025.pdf |